TY - JOUR
T1 - The St. Jude Valve prosthesis
T2 - Analysis of the clinical results in 815 implants and the need for systemic anticoagulation
AU - Myers, Mary Lee
AU - Lawrie, Gerald M.
AU - Crawford, E. Stanley
AU - Howell, Jimmy F.
AU - Morris, George C.
AU - Glaeser, Donald H.
AU - Debakey, Michael E.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1989/1
Y1 - 1989/1
N2 - Between July 1979 and December 1984, 785 patients received 815 St. Jude Medical valve prostheses. Valve-related mortality in the follow-up period was due to thromboemholism in seven cases, anticoagulant-related hemorrhage in three and perivalvular leak in two. Freedom from valve-related death or reoperation at 3 years was 96.4% for aortic valve replacement and 98.3% for mitral valve replacement. The overall rate of thromboembolism was 2.6%/patient-year with warfarin, 9.2%/patient-year with antiplatelet medication and 15.6%/patient-year in patients with no anticoagulant therapy. One episode of thrombotic obstruction of a mitral valve, in a patient receiving no anticoagulant therapy, resulted in an occurrence rate of such obstruction of 0.22%/patient-year. Valve replacement with the St. Jude valve produced excellent clinical results, but long-term anticoagulation with warfarin was required to minimize thromboembolic complications. The use of antiplatelet agents alone provided inadequate protection.
AB - Between July 1979 and December 1984, 785 patients received 815 St. Jude Medical valve prostheses. Valve-related mortality in the follow-up period was due to thromboemholism in seven cases, anticoagulant-related hemorrhage in three and perivalvular leak in two. Freedom from valve-related death or reoperation at 3 years was 96.4% for aortic valve replacement and 98.3% for mitral valve replacement. The overall rate of thromboembolism was 2.6%/patient-year with warfarin, 9.2%/patient-year with antiplatelet medication and 15.6%/patient-year in patients with no anticoagulant therapy. One episode of thrombotic obstruction of a mitral valve, in a patient receiving no anticoagulant therapy, resulted in an occurrence rate of such obstruction of 0.22%/patient-year. Valve replacement with the St. Jude valve produced excellent clinical results, but long-term anticoagulation with warfarin was required to minimize thromboembolic complications. The use of antiplatelet agents alone provided inadequate protection.
UR - http://www.scopus.com/inward/record.url?scp=0024552191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024552191&partnerID=8YFLogxK
U2 - 10.1016/0735-1097(89)90549-4
DO - 10.1016/0735-1097(89)90549-4
M3 - Article
C2 - 2909582
AN - SCOPUS:0024552191
SN - 0735-1097
VL - 13
SP - 57
EP - 62
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -